everyone. on in earnings for and Jonae, you joining Thank you, quarter fourth the since today us call last of good Thank year. investor first going afternoon, our public
XXXX can of has transformational a year is significant cure you development map are on with the road a review of clinical been share the the difference diseases, discovery From for huge a life. where there corporate unmet ahead. we antiviral treatment, founding of to our severe where and for drugs make and in the and company, need vision viral possibly patient Atea, year and and prophylaxis to medical we the happy progress for we our the have for made was
last treatment to diseases of great RNA deal a our progress available XX severe a the and diseases. have treatment the no years, of number continues remain cause many global has the in viruses over there been of While of
with platform this example COVID-XX the Early year, SARS-CoV-X. last us a caused current put of fight. our we have antiviral pandemic by perfect at the Today, forefront
to COVID-XX and become manage increasingly an this potential a be among Multiple to that will As has the treatments pandemic, circulate endemic year to preventive now SARS-CoV-X coronavirus therapeutic into virus. years. we human likely this is essential are for us
prodrugs are uniquely and properties nucleotide suited diseases. prevention pure for treatment these of have viral Our the that pharmacological
designed enzyme to polymerase, viral candidates the of RNA life replication to critical target these highly conserved are cycle a drug Our viruses.
Our offers essential activity, all when and including many of administration advantages, patients platform and of worldwide. potent millions convenience manufacturing, selective targeting all scalable antiviral
Turning COVID-XX advance patients. trial II Slide in AT-XXX, an made Phase to X. now a to moved initiating clinical With hospitalized We program, progress the year. tremendous quickly last filing we IND,
setting trial In the Phase is II addition, the in biology outpatient also ongoing.
initiating with Importantly, and clinical programs we partner, strategic Phase further quarter, Janet later call. program a provide second Roche, details anticipate on would global in the the our III in our
on manuscript, COVID-XX on publishing Antiviral Conference We favorable I results and the to highlighting AT-XXX recently In Research COVID-XX our been Agents we of results also published very in ICAR. results. International present was AT-XXX presented presenting have also invited month, at Chemotherapy. were CROI. in And Phase or March and This were Antimicrobial supportive and data at active, preclinical and
dual interactions unique to ] and this (sic) polymerase. [ with In AT-XXXX we manuscript SARS-CoV a mechanism elucidate SARS-CoV-X have diligently submitting of detailing the worked are and the action addition, against AT-XXX of RNA
we the relating groundbreaking We and review peer scientific the COVID-XX In this should on community datas with shared research the our term expect of those at in world's collaborators bioRxiv. publication to near start in be journal. meantime, the
the Phase recently on I We Turning in call. program initiated fever. Janet a our AT-XXX clinical program. Again, dengue this study details on will provide to now greater later
other we with have we the late-stage development. advance move to In programs continued training our addition, forward as over and Atea year, the last team
X. Moving Slide to
balance strong later in detail an points. development exceptionally As to our programs further through support will discuss inflection key which Andrea the call, have value-creating sheet in from the clinical we
In partnership, our in we our antiviral also fourth initial development, and manufacturing for received with executed during powerhouse quarter, With commercialization. Roche million. global public a Roche, $XXX taking the strategic offering crossover payment our an developments upfront financing with partner, global addition this global the agreement The joint responsibility a cost-sharing to of significant collaboration manufacturing. we and XX/XX for at provides
up net In potential addition million is to regulatory additional to tiered development opportunity there million sales, and sales-based in and milestones. for $XXX up for royalties for to an $XXX milestones on
COVID-XX. treatment Let's lead now may our address challenges exist prevention at of product candidate, look and the ways the currently with AT-XXX, that
of antivirals The worldwide. phase treatment to can to will plan impact early replication COVID-XX, the rapidly of infection for in is global direct-acting health. an For disease reduce that we viral or COVID-XX clinical which lead benefit role DAAs progression and all on meaningful a believe the essential inhibit
long-term in use has vaccines that on impact it potential of of COVID hospitalization, vaccines treatment to used where DAA profile, in believe similar as We influenza, on to We DAA complementary based and sequelae. an pre- the virus, have hopefully the prophylaxis post-exposure the shorten and paradigm the both AT-XXX are and drugs COVID maybe to prevent a or reduce concomitantly. view and used transmission
contrast, the antibodies relatively to administration many creating be health costly, and manufactured for care complicated challenges a is system. administered. -- DAA manufacturing and easy and and efficiently may In
globally. and COVID-XX the RNA United RNA the virus, SARS-CoV-X emerging are is which both responsible highly variants AT-XXX States. we also And South replication which with called conserved for Brazil impact Europe, and RNA U.K., viral spreading and polymerase, a transcription. rapidly an targets the protein, expected nspXX, see nonstructural Africa, As in is are
even anticipated fusion for this cell mutations antiviral spike the target, its the in will maintain AT-XXX against the recently protein emerging is conserved activity and recognition responsible it with process. whole variance that Given receptor preferential membrane
have replication. pocket domains. but its and is Moving catalytic polymerase has an viral RNA well-known there was which largely which to Slide for a function AT-XXX, RdRp, is the mentioned also template, until unknown previously, Besides end polymerase with the X terminal RNA GDP activity, NiRAN, called to we nucleotides incorporating now. nucleotidyltransferase domain biological target subunit as binding essential X. This RNA functional the has
angstrom pre-incorporation cryo AT-XXXX second to causing we is electron incorporated the in quaternary nspXX. RdRp What and obtained are the really molecules very template Its saw binding we the of RNA the interesting chain a stalled RNA including cofactors, Recently, is structure X of of -- active and templates, nspX termination. at AT-XXX. X located the complex is in into likely them the nspXX. AT-XXXX, triphosphate sites nspX microscopy and while that X.XX active the state, is metabolite X with
how next binds AT-XXXX the site, To it our interacts And molecules now with a generation binding in will binding us design is knowledge, active to an inhibitors its time blocking More inhibitor pockets, elucidated. importantly, know to X the a NiRAN since these programs. the third been function. this AT-XXXX better first ever exactly our has potentially of to NiRAN help compound we even description
We an believe SARS-CoV-X that as replication, a that in this NiRAN-dependent RNA are distinct dual X world-renowned who the discovered antiviral independent with pathways, we recently important actually AT-XXX expert Canard, mechanisms initiate synthesis. Bruno by there is highly an collaboration which on and are of because viral RNA
is RNA picornaviruses. NiRAN this is that And to similar block candidate, a first expected which the cofactor the synthesis. -- the label the then also so called the described NiRAN-dependent to pathway, which This binding nucleotide, preferably can to a the a so the only initiate with nspXX like the minus-strand protein-primed serves UMP, pathway, This our for nspX RNA function. For has previously the function. synthesis, product demonstration was primer NiRAN is its the coronavirus NiRAN-dependent as NiRAN,
The second where RNA pathway RdRp the is the which can as to initiate then synthesize a NiRAN-independent, dinucleotide, serves primer synthesis.
creating mechanism this inhibiting RdRp believe both can this with resistance the variants. and providing NiRAN a function. [ a ] broad differentiated coverage high-band product potentially product advantage dual give Our also of to can unique candidate our terms antiviral block in different us candidate We that and of
for development more intense that overview, over will Janet now call update. turn With a I clinical to the
